CA254853A
(en)
|
|
1925-10-20 |
Wyatt Prentice Frank |
Radio train stop and telephone despatching system
|
US4499289A
(en)
|
1982-12-03 |
1985-02-12 |
G. D. Searle & Co. |
Octahydronapthalenes
|
US4933438A
(en)
|
1984-02-29 |
1990-06-12 |
University Of Florida |
Brain-specific analogues of centrally acting amines
|
US4613610A
(en)
|
1984-06-22 |
1986-09-23 |
Sandoz Pharmaceuticals Corp. |
Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
|
US4686237A
(en)
|
1984-07-24 |
1987-08-11 |
Sandoz Pharmaceuticals Corp. |
Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
|
US4647576A
(en)
|
1984-09-24 |
1987-03-03 |
Warner-Lambert Company |
Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
|
US6150354A
(en)
|
1987-01-15 |
2000-11-21 |
Bonnie Davis |
Compounds for the treatment of Alzheimer's disease
|
US4871721A
(en)
|
1988-01-11 |
1989-10-03 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing squalene synthetase inhibitors
|
US4924024A
(en)
|
1988-01-11 |
1990-05-08 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
|
US5506219A
(en)
|
1988-08-29 |
1996-04-09 |
E. R. Squibb & Sons, Inc. |
Pyridine anchors for HMG-CoA reductase inhibitors
|
US5753675A
(en)
|
1989-03-03 |
1998-05-19 |
Novartis Pharmaceuticals Corporation |
Quinoline analogs of mevalonolactone and derivatives thereof
|
US5133974A
(en)
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US5312817A
(en)
|
1991-05-14 |
1994-05-17 |
Ernir Snorrason |
Treatment of fatigue syndrome
|
IT1250421B
(it)
|
1991-05-30 |
1995-04-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
|
US5595872A
(en)
|
1992-03-06 |
1997-01-21 |
Bristol-Myers Squibb Company |
Nucleic acids encoding microsomal trigyceride transfer protein
|
US5712396A
(en)
|
1992-10-28 |
1998-01-27 |
Magnin; David R. |
α-phosphonosulfonate squalene synthetase inhibitors
|
EP0671953A4
(en)
|
1992-11-13 |
1996-01-10 |
Univ Ohio State Res Found |
ANALOGS OF N- (4-HYDROXYPHENYL) RETINAMIDE-O-GLUCURONIDE ARYLAMIDE.
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
US5739135A
(en)
|
1993-09-03 |
1998-04-14 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
FR2710265B1
(fr)
|
1993-09-22 |
1995-10-20 |
Adir |
Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
|
US5620997A
(en)
|
1995-05-31 |
1997-04-15 |
Warner-Lambert Company |
Isothiazolones
|
US6548084B2
(en)
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
US6245347B1
(en)
|
1995-07-28 |
2001-06-12 |
Zars, Inc. |
Methods and apparatus for improved administration of pharmaceutically active compounds
|
AU6966696A
(en)
|
1995-10-05 |
1997-04-28 |
Warner-Lambert Company |
Method for treating and preventing inflammation and atherosclerosis
|
DE19541260A1
(de)
|
1995-11-06 |
1997-05-07 |
Lohmann Therapie Syst Lts |
Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
|
US5962440A
(en)
|
1996-05-09 |
1999-10-05 |
Bristol-Myers Squibb Company |
Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
|
US5885983A
(en)
|
1996-05-10 |
1999-03-23 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
US5827875A
(en)
|
1996-05-10 |
1998-10-27 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
US6512010B1
(en)
|
1996-07-15 |
2003-01-28 |
Alza Corporation |
Formulations for the administration of fluoxetine
|
US6011155A
(en)
|
1996-11-07 |
2000-01-04 |
Novartis Ag |
N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
US5760246A
(en)
|
1996-12-17 |
1998-06-02 |
Biller; Scott A. |
Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
|
WO1998031697A1
(en)
|
1997-01-15 |
1998-07-23 |
Sankyo Company, Limited |
Aryl c-glycoside compounds and sulfated esters thereof
|
EP1017370B1
(en)
|
1997-09-11 |
2003-10-29 |
Nycomed Danmark ApS |
MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
|
US6624200B2
(en)
|
1998-08-25 |
2003-09-23 |
Columbia Laboratories, Inc. |
Bioadhesive progressive hydration tablets
|
US6607751B1
(en)
|
1997-10-10 |
2003-08-19 |
Intellipharamaceutics Corp. |
Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
|
US6403597B1
(en)
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
US6248864B1
(en)
|
1997-12-31 |
2001-06-19 |
Adherex Technologies, Inc. |
Compounds and methods and modulating tissue permeability
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
US6312717B1
(en)
|
1998-07-07 |
2001-11-06 |
Bristol-Myers Squibb Company |
Method for treatment of anxiety and depression
|
US6197798B1
(en)
|
1998-07-21 |
2001-03-06 |
Novartis Ag |
Amino-benzocycloalkane derivatives
|
US20020009478A1
(en)
|
1998-08-24 |
2002-01-24 |
Douglas Joseph Dobrozsi |
Oral liquid mucoadhesive compositions
|
SE9802864D0
(sv)
|
1998-08-27 |
1998-08-27 |
Pharmacia & Upjohn Ab |
Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
|
US6069238A
(en)
|
1998-09-30 |
2000-05-30 |
Eli Lilly And Company |
Spirocyclic C-glycosides
|
CN1406126A
(zh)
|
1998-10-01 |
2003-03-26 |
诺瓦提斯公司 |
新型缓释口服制剂
|
US6283719B1
(en)
*
|
1998-11-05 |
2001-09-04 |
Frantz Medical Development Ltd |
Detecting obstructions in enteral/parenteral feeding tubes and automatic removal of clogs therefrom
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
US7407978B2
(en)
|
1999-04-06 |
2008-08-05 |
Theracos, Inc. |
Heterocyclic analogs of diphenylethylene compounds
|
FR2792527B1
(fr)
|
1999-04-22 |
2004-08-13 |
Ethypharm Lab Prod Ethiques |
Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques
|
US6172081B1
(en)
|
1999-06-24 |
2001-01-09 |
Novartis Ag |
Tetrahydroisoquinoline 3-carboxamide derivatives
|
US6541020B1
(en)
|
1999-07-09 |
2003-04-01 |
Trimeris, Inc. |
Methods and compositions for administration of therapeutic reagents
|
DE19933926A1
(de)
|
1999-07-20 |
2001-01-25 |
Boehringer Ingelheim Pharma |
Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6562375B1
(en)
|
1999-08-04 |
2003-05-13 |
Yamanouchi Pharmaceuticals, Co., Ltd. |
Stable pharmaceutical composition for oral use
|
WO2001015668A1
(en)
|
1999-09-02 |
2001-03-08 |
Nostrum Pharmaceuticals, Inc. |
Controlled release pellet formulation
|
US6544548B1
(en)
|
1999-09-13 |
2003-04-08 |
Keraplast Technologies, Ltd. |
Keratin-based powders and hydrogel for pharmaceutical applications
|
PH12000002657B1
(en)
*
|
1999-10-12 |
2006-02-21 |
Bristol Myers Squibb Co |
C-aryl glucoside SGLT2 inhibitors
|
US6515117B2
(en)
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US6080736A
(en)
|
1999-10-27 |
2000-06-27 |
Janus Pharmaceuticals, Inc. |
Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
|
US6461631B1
(en)
|
1999-11-16 |
2002-10-08 |
Atrix Laboratories, Inc. |
Biodegradable polymer composition
|
DE19963234A1
(de)
|
1999-12-27 |
2002-01-24 |
Boehringer Ingelheim Pharma |
Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6482439B2
(en)
|
1999-12-29 |
2002-11-19 |
Nanodelivery, Inc. |
Drug delivery system exhibiting permeability control
|
JP3897594B2
(ja)
|
2000-01-18 |
2007-03-28 |
ノバルティス アクチエンゲゼルシャフト |
ミクロソームトリグリセリド輸送タンパク質およびアポリポタンパク質分泌の阻害剤として有用なカルボキサミド
|
AU3294701A
(en)
|
2000-01-28 |
2001-08-07 |
Bristol-Myers Squibb Company |
Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
|
US6555519B2
(en)
|
2000-03-30 |
2003-04-29 |
Bristol-Myers Squibb Company |
O-glucosylated benzamide SGLT2 inhibitors and method
|
US6683056B2
(en)
|
2000-03-30 |
2004-01-27 |
Bristol-Myers Squibb Company |
O-aryl glucoside SGLT2 inhibitors and method
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
US6524621B2
(en)
|
2000-05-01 |
2003-02-25 |
Aeropharm Technology Inc. |
Core formulation
|
US6432969B1
(en)
|
2000-06-13 |
2002-08-13 |
Novartis Ag |
N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
US6482440B2
(en)
|
2000-09-21 |
2002-11-19 |
Phase 2 Discovery, Inc. |
Long acting antidepressant microparticles
|
CA2429426A1
(en)
|
2000-11-17 |
2002-05-23 |
Takeda Chemical Industries, Ltd. |
Isoxazole derivatives
|
US6670380B2
(en)
|
2000-11-20 |
2003-12-30 |
Bristol-Myers Squibb Co. |
Pyridone inhibitors of fatty acid binding protein and method
|
TWI255817B
(en)
|
2001-02-14 |
2006-06-01 |
Kissei Pharmaceutical |
Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
|
US6524615B2
(en)
|
2001-02-21 |
2003-02-25 |
Kos Pharmaceuticals, Incorporated |
Controlled release pharmaceutical composition
|
US6936590B2
(en)
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
DK1385856T3
(da)
|
2001-04-11 |
2006-05-15 |
Bristol Myers Squibb Co |
Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
|
US6869947B2
(en)
|
2001-07-03 |
2005-03-22 |
Novo Nordisk A/S |
Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
US6919323B2
(en)
|
2001-07-13 |
2005-07-19 |
Bristol-Myers Squibb Company |
Pyridazinone inhibitors of fatty acid binding protein and method
|
EP1432720A1
(en)
|
2001-09-05 |
2004-06-30 |
Bristol-Myers Squibb Company |
O-pyrazole glucoside sglt2 inhibitors and method of use
|
JP2003080635A
(ja)
*
|
2001-09-12 |
2003-03-19 |
Teijin Meton Kk |
合成樹脂複合構造体、それからなる浴室構成品及びその製造方法
|
AU2002348276A1
(en)
|
2001-11-16 |
2003-06-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US6727261B2
(en)
|
2001-12-27 |
2004-04-27 |
Hoffman-La Roche Inc. |
Pyrido[2,1-A]Isoquinoline derivatives
|
PL210710B1
(pl)
|
2002-03-22 |
2012-02-29 |
Kissei Pharmaceutical |
Krystaliczne postaci 2-(4-metoksybenzylo) fenylo-6-O-etoksykarbonylo-ß-D-glukopiranozydu, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna
|
US6710040B1
(en)
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
ATE469161T1
(de)
|
2002-08-08 |
2010-06-15 |
Kissei Pharmaceutical |
Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
|
NZ535229A
(en)
|
2002-08-09 |
2006-05-26 |
Taisho Pharmaceutical Co Ltd |
Aryl 5-thio-beta-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
|
US6700238B1
(en)
*
|
2002-08-13 |
2004-03-02 |
Wei Tong |
Generator gas shield and related method
|
DE10258008B4
(de)
|
2002-12-12 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
BR0317929A
(pt)
|
2003-01-03 |
2006-04-11 |
Bristol Myers Squibb Co |
métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
|
KR101001848B1
(ko)
|
2003-03-14 |
2010-12-17 |
고토부키 세이야쿠 가부시키가이샤 |
C-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물
|
JP2004300102A
(ja)
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
CA2549015A1
(en)
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted fused heterocyclic c-glycosides
|
TW200524951A
(en)
|
2003-08-01 |
2005-08-01 |
Janssen Pharmaceutica Nv |
Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
|
ME00411B
(me)
|
2003-08-01 |
2011-10-10 |
Tanabe Seiyaku Co |
Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
|
DE502004008951D1
(de)
|
2003-08-26 |
2009-03-19 |
Boehringer Ingelheim Pharma |
Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US7375090B2
(en)
|
2003-08-26 |
2008-05-20 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
|
US7371732B2
(en)
|
2003-12-22 |
2008-05-13 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
|
DE10361133A1
(de)
|
2003-12-22 |
2005-07-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
EP1721904A4
(en)
|
2004-03-04 |
2010-07-14 |
Kissei Pharmaceutical |
HETEROCYCLIC DERIVED FADE; MEDICAL COMPOSITION CONTAINING THE DERIVATIVE AND MEDICAL USE
|
KR20120007088A
(ko)
|
2004-03-16 |
2012-01-19 |
베링거 인겔하임 인터내셔날 게엠베하 |
글루코피라노실-치환된 벤졸 유도체, 당해 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법
|
CA2560005A1
(en)
|
2004-03-31 |
2005-10-13 |
Kissei Pharmaceutical Co., Ltd. |
Phenol derivative, medicinal composition containing the same, and medicinal use thereof
|
US7393836B2
(en)
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
DE102004034690A1
(de)
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
JP2008508213A
(ja)
|
2004-07-27 |
2008-03-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
|
WO2006018150A1
(de)
|
2004-08-11 |
2006-02-23 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
ATE407938T1
(de)
|
2004-12-16 |
2008-09-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
TW200637839A
(en)
|
2005-01-07 |
2006-11-01 |
Taisho Pharmaceutical Co Ltd |
1-thio-d-glucitol derivatives
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
CA2595257A1
(en)
|
2005-02-23 |
2006-08-31 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
|
AR053710A1
(es)
|
2005-04-11 |
2007-05-16 |
Xenon Pharmaceuticals Inc |
Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
|
ATE453656T1
(de)
|
2005-04-15 |
2010-01-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(en)
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
JP2007007628A
(ja)
*
|
2005-07-04 |
2007-01-18 |
Hokkaido Univ |
セメントコンクリートの中性化促進方法
|
TW200726755A
(en)
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
DE602006014411D1
(de)
|
2005-07-27 |
2010-07-01 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte ((hetero)cycloalyklethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters (sglt)
|
GB0516156D0
(en)
|
2005-08-05 |
2005-09-14 |
Eisai London Res Lab Ltd |
JNK inhibitors
|
CA2620566A1
(en)
|
2005-08-30 |
2007-03-08 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
AU2006289093A1
(en)
|
2005-09-08 |
2007-03-15 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
TWI370818B
(en)
|
2006-04-05 |
2012-08-21 |
Astellas Pharma Inc |
Cocrystal of c-glycoside derivative and l-proline
|
JP5067644B2
(ja)
|
2006-05-19 |
2012-11-07 |
大正製薬株式会社 |
C−フェニルグリシト−ル化合物
|
EP2019679B1
(en)
|
2006-05-23 |
2018-06-20 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
US7919598B2
(en)
*
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080027014A1
(en)
|
2006-07-28 |
2008-01-31 |
Tanabe Seiyaku Co., Ltd. |
Novel SGLT inhibitors
|
WO2008049923A1
(en)
|
2006-10-27 |
2008-05-02 |
Boehringer Ingelheim International Gmbh |
CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
JP5583003B2
(ja)
|
2007-04-02 |
2014-09-03 |
セラコス・インコーポレイテッド |
ベンジルグルコシド誘導体およびその用途
|
US20080287529A1
(en)
*
|
2007-05-18 |
2008-11-20 |
Bristol-Myers Squibb Company |
Crystal structures of sglt2 inhibitors and processes for preparing same
|
CN101801989B
(zh)
*
|
2007-07-26 |
2015-11-25 |
莱西肯医药有限公司 |
用于制备钠-葡萄糖协同转运蛋白2抑制剂的方法和化合物
|
CA2697349C
(en)
|
2007-08-23 |
2012-04-24 |
Theracos, Inc. |
Benzylbenzene derivatives and methods of use
|
RS56990B1
(sr)
|
2007-09-10 |
2018-05-31 |
Janssen Pharmaceutica Nv |
Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
|
CL2009000309A1
(es)
*
|
2008-02-13 |
2009-06-26 |
Sanofi Aventis |
Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
|
EP2312944B1
(en)
|
2008-07-15 |
2018-09-05 |
Theracos, Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
ES2599330T3
(es)
*
|
2008-08-22 |
2017-02-01 |
Theracos Sub, Llc |
Proceso para la preparación de inhibidores de SGLT2
|
TW201023858A
(en)
*
|
2008-09-18 |
2010-07-01 |
Ortho Mcneil Janssen Pharm |
Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|